Clinical Trial Update: Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating subcutaneous epcoritamab plus intravenous rituximab and oral lenalidomide (R2) in adults with previously untreated follicular lymphom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Epcoritamab (epcoritamab)
• Lenalidomide (lenalidomide)
• Rituximab (rituximab)

Snippet

Sponsor: Genmab | Conditions: Follicular Lymphoma (FL) | Phase 3 | Status: RECRUITING